Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $24.15 in the prior trading day, Moderna Inc (NASDAQ: MRNA) closed at $24.75, up 2.48%. In other words, the price has increased by $2.48 from its previous closing price. On the day, 6.63 million shares were traded. MRNA stock price reached its highest trading level at $24.795 during the session, while it also had its lowest trading level at $23.99.
Ratios:
Our goal is to gain a better understanding of MRNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.73 and its Current Ratio is at 3.93. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Neutral rating and assigned the stock a target price of $40.
On February 18, 2025, Barclays Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $111 to $45. Goldman Downgraded its Buy to Neutral on January 29, 2025, whereas the target price for the stock was revised from $99 to $51.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 11 ’25 when Hussain Abbas sold 312 shares for $28.00 per share. The transaction valued at 8,736 led to the insider holds 580 shares of the business.
Hussain Abbas bought 312 shares of MRNA for $8,736 on Jun 11 ’25. On Mar 03 ’25, another insider, Bancel Stephane, who serves as the Chief Executive Officer of the company, bought 160,314 shares for $31.22 each. As a result, the insider paid 5,004,318 and bolstered with 9,210,686 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 9670657024 and an Enterprise Value of 5899317760. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.33 while its Price-to-Book (P/B) ratio in mrq is 1.04. Its current Enterprise Value per Revenue stands at 2.643 whereas that against EBITDA is -1.812.
Stock Price History:
The Beta on a monthly basis for MRNA is 1.13, which has changed by -0.44342017 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, MRNA has reached a high of $48.92, while it has fallen to a 52-week low of $22.28. The 50-Day Moving Average of the stock is -4.35%, while the 200-Day Moving Average is calculated to be -11.37%.
Shares Statistics:
The stock has traded on average 11.69M shares per day over the past 3-months and 10902340 shares per day over the last 10 days, according to various share statistics. A total of 391.00M shares are outstanding, with a floating share count of 346.52M. Insiders hold about 11.30% of the company’s shares, while institutions hold 70.22% stake in the company. Shares short for MRNA as of 1763078400 were 64356094 with a Short Ratio of 5.45, compared to 1760486400 on 65036951. Therefore, it implies a Short% of Shares Outstanding of 64356094 and a Short% of Float of 20.02.
Earnings Estimates
The firm’s stock currently is rated by 10.0 analysts. The consensus estimate for the next quarter is -$2.44, with high estimates of -$2.18 and low estimates of -$2.83. Analysts are recommending an EPS of between -$7.47 and -$9.54 for the fiscal current year, implying an average EPS of -$8.08. EPS for the following year is -$7.15, with 16.0 analysts recommending between -$4.47 and -$8.38.
Revenue Estimates
12 analysts predict $626.35M in revenue for . The current quarter. It ranges from a high estimate of $836.4M to a low estimate of $467M. As of . The current estimate, Moderna Inc’s year-ago sales were $966MFor the next quarter, 12 analysts are estimating revenue of $187.98M. There is a high estimate of $279M for the next quarter, whereas the lowest estimate is $58.1M.
A total of 19 analysts have provided revenue estimates for MRNA’s current fiscal year. The highest revenue estimate was $2.1B, while the lowest revenue estimate was $1.73B, resulting in an average revenue estimate of $1.89B. In the same quarter a year ago, actual revenue was $3.24BBased on 20 analysts’ estimates, the company’s revenue will be $1.91B in the next fiscal year. The high estimate is $2.34B and the low estimate is $1.36B.
